Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Entero Therapeutics ( (ENTO) ) has provided an announcement.
On May 8, 2025, Entero Therapeutics‘ subsidiary, ImmunogenX, LLC, finalized a settlement agreement with Mattress Liquidators Inc., resolving financial obligations and agreeing to amended loan terms. The agreement includes a payment of $5.5 million to the plaintiff and a revolving loan commitment, with the plaintiff releasing its security interest in ImmunogenX. Additionally, Entero Therapeutics announced its 2025 Annual Meeting of Stockholders will be held on June 27, 2025, with deadlines set for stockholder proposals.
The most recent analyst rating on (ENTO) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Entero Therapeutics stock, see the ENTO Stock Forecast page.
More about Entero Therapeutics
Average Trading Volume: 671,035
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2M
For an in-depth examination of ENTO stock, go to TipRanks’ Stock Analysis page.